American Society of Clinical Oncology

SHERPA: White

People

  1. Danila
    Danila
  2. Scher
    Scher
  3. Fleisher
    Fleisher
  4. Heller
    Heller
  5. Fox
    Fox
  6. Lilja
    Lilja
  7. Morris
    Morris
  8. Sawyers
    Sawyers
  9. Schultz
    Schultz
  10. Slovin
    Slovin

Groups

  1. Department of Medicine (10)
  2. Genitourinary Oncology Service (10)
  3. Solid Tumor Oncology Division (10)
  4. GSK Faculty (5)
  5. Biostatistics Service (4)
  6. Epidemiology and Biostatistics (4)
  7. Human Oncology and Pathogenesis Program (4)
  8. Hematologic Malignancies, Division of (3)
  9. Center for Hematologic Malignancies (2)
  10. Computational Oncology Service (2)
Search Within
  1. "Daniel Danila"
  2. "2013"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (1)
Groups
  1. Department of Medicine (10)
  2. Genitourinary Oncology Service (10)
  3. Solid Tumor Oncology Division (10)
  4. GSK Faculty (5)
  5. Biostatistics Service (4)
  6. Epidemiology and Biostatistics (4)

More Groups

People
  1. Daniel Danila (10)
  2. Howard Scher (8)
  3. Martin Fleisher (6)
  4. Aseem Anand (5)
  5. Amrita Herkal (3)
  6. Chintan Patel (3)

More People

Years
  1. 2013 (10)
Publications
  1. Journal of Clinical Oncology (10)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D. C.; Anand, A.; Heller, G.; Wan, M.; Herkal, A.; Patel, C.; Khanin, R.; Schultz, N.; Lilja, H.; Fleisher, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Genomic heterogeneity of circulating tumor cells in castration-resistant prostate cancer (CRPC) revealed by single-cell sequencing
    Meeting Abstract

    Welsh, A.; Danila, D. C.; Anand, A.; Kendall, J.; Sawyers, C. L.; Fleisher, M.; Wigler, M.; Hicks, J. B.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer
    Meeting Abstract

    Subudhi, S. K.; Heller, G.; Danila, D. C.; Anand, A.; Lacuna, K. P.; Samoila, A.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A pilot study comparing circulation tumor cells (CTC) detection by AdnaTest prostate assay to CellSearch in patients (pts) with castration resistant prostate cancer (CRPC)
    Meeting Abstract

    Samoila, A.; Bastos, D. A.; Herkal, A.; Patel, C.; Curtis, K. R.; Schreiber, N. A.; Anand, A.; Fleisher, M.; Scher, H. I.; Danila, D. C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D. C.; Szmulewitz, R. Z.; Higano, C. S.; Gilbert, H.; Kahn, R. S.; Wood, K.; Agarwal, P.; Lin, K.; Kabbarah, O.; Fine, B. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Bianchini, D.; Omlin, A. G.; Pezaro, C. J.; Mukherji, D.; Estelles, D. L.; Zivi, A.; Ferraldeschi, R.; Crespo, M.; Buchbinder, A.; Attard, G.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer
    Meeting Abstract

    Beltran, H.; Rubin, M. A.; Mosquera, J. M.; Christos, P. J.; Calukovic, O.; Karpenko, I.; Pinski, J. K.; Danila, D. C.; Nanus, D. M.; Tagawa, S. T.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Anand, A.; Danila, D. C.; Heller, G.; Herkal, A.; Patel, C.; Khanin, R.; Schultz, N.; Lilja, H.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Morris, M. J.; Fox, J. J.; Danila, D. C.; Slovin, S. F.; Hager, J. H.; Rix, P. J.; Chow-Maneval, E.; Chen, I.; Gonen, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save